CLINICAL TRIALS PROFILE FOR SOLRIAMFETOL
✉ Email this page to a colleague
All Clinical Trials for Solriamfetol
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT02806895 ↗ | Study Assessing Effects of JZP-110 on Driving Performance in the Treatment of Excessive Sleepiness in OSA | Completed | Jazz Pharmaceuticals | Phase 2 | 2016-07-05 | This trial is a randomized, double-blind, placebo-controlled, crossover study to evaluate the effect of JZP-110 on driving performance in subjects with excessive sleepiness due to obstructive sleep apnea. |
NCT02806908 ↗ | Study Assessing Effects of JZP-110 on Driving Performance in the Treatment of Excessive Sleepiness in Narcolepsy | Completed | Jazz Pharmaceuticals | Phase 2 | 2016-06-01 | This trial is a randomized, double-blind, placebo-controlled, crossover study to evaluate the effect of JZP-110 on driving performance in subjects with excessive sleepiness due to narcolepsy. |
NCT03868943 ↗ | Solriamfetol in Improving Sleep in Patients With Grade II-IV Glioma | Recruiting | National Cancer Institute (NCI) | Phase 2 | 2021-01-27 | This phase II trial studies the side effects of solriamfetol in improving sleep in patients with grade II-IV glioma. Solriamfetol is a wakefulness-promoting drug. Giving solriamfetol may improve sleep, memory, fatigue, mood, or quality of life in patients with brain tumors (gliomas). |
NCT03868943 ↗ | Solriamfetol in Improving Sleep in Patients With Grade II-IV Glioma | Recruiting | Wake Forest University Health Sciences | Phase 2 | 2021-01-27 | This phase II trial studies the side effects of solriamfetol in improving sleep in patients with grade II-IV glioma. Solriamfetol is a wakefulness-promoting drug. Giving solriamfetol may improve sleep, memory, fatigue, mood, or quality of life in patients with brain tumors (gliomas). |
NCT04602936 ↗ | Solriamfetol in Binge Eating Disorder | Not yet recruiting | Jazz Pharmaceuticals | Phase 4 | 2020-11-15 | The goal of this project is to evaluate the efficacy and tolerability of the novel dopamine and norepinephrine reuptake inhibitor (DNRI) solriamfetol in the treatment of binge eating disorder (BED). |
NCT04602936 ↗ | Solriamfetol in Binge Eating Disorder | Not yet recruiting | Lindner Center of HOPE | Phase 4 | 2020-11-15 | The goal of this project is to evaluate the efficacy and tolerability of the novel dopamine and norepinephrine reuptake inhibitor (DNRI) solriamfetol in the treatment of binge eating disorder (BED). |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Solriamfetol
Condition Name
Clinical Trial Locations for Solriamfetol
Trials by Country
Clinical Trial Progress for Solriamfetol
Clinical Trial Phase
Clinical Trial Sponsors for Solriamfetol
Sponsor Name